Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 14/20 | 0.62 |
| ▸ | TGM2 | P21980 | 3/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8874235 | 0.94 | CES1 (0.55) | CES1TGM2DNMT1CYP3A4GRIN2D | |
| SCHEMBL9055026 | 0.83 | CES1 (0.45) | CES1TGM2DNMT1ALDH1A1 | |
| SCHEMBL9055029 | 0.83 | CES1 (0.45) | CES1TGM2DNMT1ALDH1A1 | |
| SCHEMBL7048416 | 0.81 | CES1 (0.46) | CES1TGM2DNMT1ALDH1A1 | |
| SCHEMBL7048414 | 0.81 | CES1 (0.46) | CES1TGM2DNMT1ALDH1A1 | |
| SCHEMBL7050694 | 0.81 | CES1 (0.42) | CES1TGM2DNMT1CA1CA2 | |
| SCHEMBL7050698 | 0.81 | CES1 (0.42) | CES1TGM2DNMT1CA1CA2 | |
| SCHEMBL8872671 | 0.79 | CES1 (0.41) | CES1TGM2DNMT1CA1CA2 | |
| SCHEMBL8872679 | 0.79 | CES1 (0.41) | CES1TGM2DNMT1CA1CA2 | |
| SCHEMBL5893664 | 0.78 | CES1 (0.51) | CES1TGM2DNMT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107903269-B | Preparation method of anagrelide trichloro derivative | 湖北省宏源药业科技股份有限公司 | 2021-05-04 | — | — | CN | claimed |
| CN-107903269-B | Preparation method of anagrelide trichloro derivative | 湖北省宏源药业科技股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-107903269-B | Preparation method of anagrelide trichloro derivative | 湖北省宏源药业科技股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
| US-5597922-A | Glycine receptor antagonist pharmacophore | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1997-01-28 | — | — | US | disclosed |
| WO-1996004288-A1 | GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | CES1 2260/4885TGM2 4068/4885DNMT1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.